Post-acute high-risk follow-up
Clear after-discharge logic for patients with elevated risk.
Heart attack and stroke
Markets & Business
Clinical entry first, platform upside second.
Synra starts where follow-up pressure, measurable risk and clinical workflows create a credible market. The platform opportunity expands after validation, modules, partner integrations and regional scale.
Markets
Start with clinically logical entry paths, not a generic wellness market.
The entry region is a substantial European healthcare market. Six indications are grouped into three paths so investors can understand the clinical logic quickly.
Therapy and trajectory control
Continuous visibility between appointments and treatment cycles.
Oncology and epilepsyChronic and functional burden patterns
Large patient groups with patterns across triggers, sleep, stress and activity.
Migraine, chronic pain and burnout-related burden| Clinical area | Entry-region pool | Conversion rates | New subscriptions Y1 / Y2 / Y3 | Synra focus |
|---|---|---|---|---|
| Stroke | 370,000-386,000 strokes per year; subscription pool: 88,000-94,000 recurrent strokes | 1.0% / 2.0% / 3.5% | 880-940 / 1,760-1,880 / 3,080-3,290 | Recurrence monitoring and neurological follow-up |
| Heart attack | 261,000-288,000 acute cases per year; subscription pool: 235,000-259,000 first-year follow-up patients | 0.75% / 1.5% / 2.5% | 1,760-1,940 / 3,530-3,890 / 5,880-6,480 | Post-acute cardiovascular follow-up; 18.3% one-year composite risk after first MI |
| Oncology | 800,000-850,000 new cancer cases per year; around 2.9M five-year prevalence cases | 0.25% / 0.75% / 1.5% | 2,000-2,130 / 6,000-6,380 / 12,000-12,750 | Treatment monitoring, side effects, biomarker trends and aftercare |
| Migraine and chronic pain | 14-15M people affected | 0.02% / 0.05% / 0.10% | 2,800-3,000 / 7,000-7,500 / 14,000-15,000 | Trajectory patterns, triggers and therapy response |
| Epilepsy | 0.9-1.3M active epilepsy patients | 0.05% / 0.10% / 0.20% | 450-650 / 900-1,300 / 1,800-2,600 | Seizure trajectories, triggers, sleep, adherence and drug-resistant disease patterns |
| Burnout-related burden | 11-18M relevant burden groups | 0.01% / 0.03% / 0.06% | 1,100-1,800 / 3,300-5,400 / 6,600-10,800 | Sleep, activity, stress profiles and load monitoring |
Evidence base
Market ranges are grounded in clinical registries, public health datasets and peer-reviewed sources.
Investor map
The story separates core revenue from upside.
This keeps the initial case credible: clinical follow-up and therapy monitoring first, then broader ecosystem and consumer-health optionality.
Deployable clinical endpoint and recurring monthly platform access.
Stroke, cardiovascular, oncology, epilepsy and chronic-pattern programs.
Validated third-party modules, diagnostics and governed data programs.
Business
Revenue architecture built around recurring clinical use.
The base business case is based on post-acute follow-up, therapy monitoring and trajectory control. Longevity, wellness and self-pay healthspan markets are upside, not the core model.
Clinical core
A credible, defensible entry market anchored in AI-enabled medical devices, remote monitoring and connected healthcare platforms.
TAM: USD 75-130BLongevity and consumer health
A larger second-phase opportunity. It is deliberately excluded from the base clinical ramp-up, but becomes accessible after clinical validation. The TAM anchor is about 14-24x larger than the clinical TAM.
TAM anchor: USD 1.8T; 14-24x clinical TAMPlatform ecosystem
The valuation logic moves from device maker to platform when Synra earns from validated third-party modules, integrations and licensing.
Digital health range: USD 347B-1.83TLongevity as valuation upside
Synra can enter longevity through clinical credibility, not wellness noise.
The base case remains clinical. The upside is that the same home endpoint can later support healthspan intelligence: biomarker modules, preventive programs, executive health pilots, longevity clinics and premium self-pay subscriptions.
Clinical start
Trust
Validation, workflows and longitudinal signal quality.
Clinical validation
Healthspan services
Second horizon
14-24x
USD 1.8T longevity and consumer-health TAM anchor.
| Year | New subscriptions | Subscription revenue | Hardware revenue | Total regional revenue |
|---|---|---|---|---|
| Year 1 | 9,000-10,500 | EUR 2.7-3.2M | EUR 6.8-7.9M | EUR 9.5-11.0M |
| Year 2 | 22,500-26,400 | EUR 9.5-11.1M | EUR 16.9-19.8M | EUR 26.3-30.9M |
| Year 3 | 43,400-51,000 | EUR 22.5-26.4M | EUR 32.6-38.3M | EUR 55.0-64.6M |
Entry region: DACH, the Netherlands and Belgium. Cumulative total revenue after year 3: approximately EUR 90.8-106.5M.
Industrial market perspective
Scale by multiplying validated entry-region economics, not by counting global disease cases.
The first industrial-market corridor covers the EU, Switzerland, North America, Japan and Oceania: roughly 980-990M people, or about 7.4x the entry region. This creates a modeled range of EUR 69.9-81.6M in year 1, EUR 264.7-310.0M in year 2 and EUR 671.9-788.2M in year 3.
Execution focus:
Near-term value is anchored in the clinical platform. Longevity,
consumer health, third-party app revenue and licensing remain upside
layers that depend on validation, reach, ecosystem adoption and
regulatory execution.
Roadmap
A 36-month build path from architecture to regional expansion.
The financing logic starts with prototype design and a deployable MVP, followed by seed funding for validation, production readiness, team build-out, clinical integration and regional expansion.
Prototype design
Target architecture, hardware concept, security, interfaces, clinic connection and regulatory structure.
EUR 1.2 millionDeployable MVP
Product-near MVP version for clinical pilots and controlled market entry.
EUR 1.2 millionRegional expansion
Rollout into additional developed healthcare systems, especially wider EU, North America, Japan and Oceania.
Seed: EUR 25-50MSeries A preparation
Accelerated international scale, more modules, partner ecosystem and regulatory internationalization.
Strategic scale-upImpact metrics
Connected patients, active modules, detected risk signals, response times, adherence and reduced unplanned revisits.
Exit perspective
Strategic relevance for MedTech, digital health, diagnostics, clinic software, health data, cloud and home-care infrastructure.
Societal logic
Better home visibility can support SDG 3, healthcare infrastructure, reduced inequality for mobility-limited patients and fewer unnecessary journeys.
Contact
For questions about Synra, the build path or potential conversations, contact us directly.
For investor conversations, clinical partnerships or product development discussions, Synra can provide deeper diligence materials directly.